EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Use of adenine base editing and homology-independent targeted integration strategies to correct the cystic fibrosis causing variant, W1282X

Karen Mention, Kader Cavusoglu-Doran, Anya T Joynt, Lúcia Santos, David Sanz, Alice C Eastman iD, Christian Merlo, Elinor Langfelder-Schwind, Martina F Scallan, Carlos M Farinha, Garry R Cutting, Neeraj Sharma und 1 weitere

Human Molecular Genetics · 17.11.2023 · 32 (23) · 3237-3248

DOI: 10.1093/hmg/ddad143 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Molecular Genetics, online erschienen am 31.08.2023. Verfasst von Karen Mention und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, University College Cork, College Road, Cork, T12 K8AF, Ireland. Hauptthemen laut MEDLINE: Cystic Fibrosis. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cystic Fibrosis Foundation, Cystic Fibrosis Trust, Research Innovation award from Vertex Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Small molecule drugs known as modulators can treat ~90% of people with cystic fibrosis (CF), but do not work for premature termination codon variants such as W1282X (c.3846G>A). Here we evaluated two gene editing strategies, Adenine Base Editing (ABE) to correct W1282X, and Homology-Independent Targeted Integration (HITI) of a CFTR superexon comprising exons 23–27 (SE23–27) to enable expression of a CFTR mRNA without W1282X. In Flp-In-293 cells stably expressing a CFTR expression minigene bearing W1282X, ABE corrected 24% of W1282X alleles, rescued CFTR mRNA from nonsense mediated decay and restored protein expression. However, bystander editing at the adjacent adenine (c.3847A>G), caused an amino acid change (R1283G) that affects CFTR maturation and ablates ion channel activity. In primary human nasal epithelial cells homozygous for W1282X, ABE corrected 27% of alleles, but with a notably lower level of bystander editing, and CFTR channel function was restored to 16% of wild-type levels. Using the HITI approach, correct integration of a SE23–27 in intron 22 of the CFTR locus in 16HBEge W1282X cells was detected in 5.8% of alleles, resulting in 7.8% of CFTR transcripts containing the SE23–27 sequence. Analysis of a clonal line homozygous for the HITI-SE23–27 produced full-length mature protein and restored CFTR anion channel activity to 10% of wild-type levels, which could be increased three-fold upon treatment with the triple combination of CF modulators. Overall, these data demonstrate two different editing strategies can successfully correct W1282X, the second most common class I variant, with a concomitant restoration of CFTR function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisHumansCystic Fibrosis Transmembrane Conductance RegulatorGene EditingCodon, NonsenseRNA, MessengerMutation

Stichwörter der Autor:innen

CFTRCRISPRHITIW1282Xadenine base editing

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorCodon, NonsenseRNA, Messenger

Autor:innen und Institutionen

  • Department of Physiology, University College Cork, College Road, Cork, T12 K8AF, Ireland.
  • School of Microbiology, University College Cork, College Road, Cork, T12 K8AF, Ireland.
  • McKusick-Nathans Department of Genetic Medicine, Johns Hopkins University, 3400 N. Charles Street, Baltimore, MD 21218, United States.
  • Faculty of Sciences, BioISI - Biosystems & Integrative Sciences Institute, University of Lisboa, Campo Grande, C8 bdg, Lisboa 1749-016, Portugal.
  • Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins Hospital, 1800 Orleans St, Baltimore, MD 21287, United States.
  • The Cystic Fibrosis Center, Lenox Hill Hospital, 100 E. 77th Street, 4E, New York, NY 10075, United States.

ORCID-Profile: Alice C Eastman, Patrick T Harrison

Förderung

  • Cystic Fibrosis Foundation
  • Cystic Fibrosis Trust
  • Research Innovation award from Vertex Pharmaceuticals
  • Centre grants from Fundação para a Ciência e a Tecnologia, Portugal
  • Fundação para a Ciência e a Tecnologia

Zitieren

APA

Mention, K., Cavusoglu-Doran, K., Joynt, A. T., Santos, L., Sanz, D., Eastman, A. C., Merlo, C., Langfelder-Schwind, E., Scallan, M. F., Farinha, C. M., Cutting, G. R., Sharma, N., & Harrison, P. T. (2023). Use of adenine base editing and homology-independent targeted integration strategies to correct the cystic fibrosis causing variant, W1282X. Human Molecular Genetics, 32(23), 3237-3248. https://doi.org/10.1093/hmg/ddad143

Vancouver

Mention K, Cavusoglu-Doran K, Joynt AT, Santos L, Sanz D, Eastman AC, et al. Use of adenine base editing and homology-independent targeted integration strategies to correct the cystic fibrosis causing variant, W1282X. Human Molecular Genetics. 2023;32(23):3237-3248. doi:10.1093/hmg/ddad143

BibTeX
@article{Mention2023,
  author = {Mention, Karen and Cavusoglu-Doran, Kader and Joynt, Anya T and Santos, Lúcia and Sanz, David and Eastman, Alice C and Merlo, Christian and Langfelder-Schwind, Elinor and Scallan, Martina F and Farinha, Carlos M and Cutting, Garry R and Sharma, Neeraj and Harrison, Patrick T},
  title = {Use of adenine base editing and homology-independent targeted integration strategies to correct the cystic fibrosis causing variant, W1282X},
  journal = {Human Molecular Genetics},
  year = {2023},
  volume = {32},
  number = {23},
  pages = {3237--3248},
  doi = {10.1093/hmg/ddad143}
}
Kostenlos starten →